The emerging role of CXC chemokines in epithelial ovarian cancer
- PMID: 22771929
- DOI: 10.1530/REP-12-0153
The emerging role of CXC chemokines in epithelial ovarian cancer
Abstract
In recent years, chemokines have generated intense investigations due to their involvement in both physiological and pathological processes of inflammation, particularly in ovarian biology. The physiological process of ovulation in the normal ovary involves various chemokines that mediate the healing of the ruptured endometrium. It is now being reported that many of these chemokines are also associated with the cancer of the ovary. Chronic inflammation underlies the progression of ovarian cancer; therefore, it raises the possibility that chemokines are involved in the inflammatory process and mediate immune responses that may favour or inhibit tumour progression. Ovarian cancer is a gynaecological cancer responsible for highest rate of mortality in women. Although there have been several investigations and advances in surgery and chemotherapy, the survival rate for this disease remains low. This is mainly because of a lack of specific symptoms and biomarkers for detection. In this review, we have discussed the emerging role of the CXC chemokines in epithelial ovarian cancer (EOC). The CXC group of chemokines is gaining importance in the field of ovarian cancer for being angiostatic and angiogenic in function. While there have been several studies on the angiogenesis function, emerging research shows that ELR(-) CXC chemokines, CXCL9 and CXCL10, are angiostatic. Importantly, the angiostatic chemokines can inhibit the progression of EOC. Given that there are currently no biomarkers or specific therapeutic targets for the disease, these chemokines are emerging as promising targets for therapy.
Similar articles
-
Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy.Arthritis Rheum. 2005 Oct;52(10):3175-80. doi: 10.1002/art.21303. Arthritis Rheum. 2005. PMID: 16200621
-
Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis?Rheumatol Int. 2007 Aug;27(10):969-73. doi: 10.1007/s00296-007-0317-6. Epub 2007 Jan 31. Rheumatol Int. 2007. PMID: 17265155
-
Cancer CXC chemokine networks and tumour angiogenesis.Eur J Cancer. 2006 Apr;42(6):768-78. doi: 10.1016/j.ejca.2006.01.006. Epub 2006 Feb 28. Eur J Cancer. 2006. PMID: 16510280 Review.
-
The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis.Hum Gene Ther. 2000 Jan 20;11(2):247-61. doi: 10.1089/10430340050015996. Hum Gene Ther. 2000. PMID: 10680839
-
CXC chemokines in angiogenesis.Cytokine Growth Factor Rev. 2005 Dec;16(6):593-609. doi: 10.1016/j.cytogfr.2005.04.007. Epub 2005 Jul 19. Cytokine Growth Factor Rev. 2005. PMID: 16046180 Review.
Cited by
-
CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.World J Gastroenterol. 2014 Feb 21;20(7):1681-93. doi: 10.3748/wjg.v20.i7.1681. World J Gastroenterol. 2014. PMID: 24587647 Free PMC article. Review.
-
Effects of leptin on the viability of human ovarian cancer cells and changes in cytokine expression levels.PeerJ. 2023 Apr 20;11:e15246. doi: 10.7717/peerj.15246. eCollection 2023. PeerJ. 2023. PMID: 37155466 Free PMC article.
-
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.Cell. 2017 Aug 24;170(5):927-938.e20. doi: 10.1016/j.cell.2017.07.025. Cell. 2017. PMID: 28841418 Free PMC article.
-
Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.Front Immunol. 2023 Apr 5;14:1164408. doi: 10.3389/fimmu.2023.1164408. eCollection 2023. Front Immunol. 2023. PMID: 37090728 Free PMC article.
-
Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer.Diagnostics (Basel). 2021 Jun 7;11(6):1048. doi: 10.3390/diagnostics11061048. Diagnostics (Basel). 2021. PMID: 34200333 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
